Roche Seen Offering NICE Further Price Cut For MS Drug Ocrevus
Executive Summary
UK HTA provisionally tells Roche price for supplying MS blockbuster Ocrevus to the NHS not good enough – 'try again'.
You may also be interested in...
Discounts Help Prompt UK’s NICE Turnaround on Dupixent and Ocrevus
After initially saying no, the UK health technology appraisal body, NICE, has recommended for use on the National Health Service Sanofi/Regeneron’s Dupixent and Roche’s Ocrevus. Confidential discounts helped convince NICE.
Roche Set For Disruptive Entry To MS Market With 'Brave' Ocrevus Pricing Strategy
Roche is taking no chances with its newly approved multiple sclerosis drug Ocrevus and has set a cost that ensures price is no barrier to treatment.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.